Literature DB >> 26669674

The right dose for every patient: a key step for precision medicine.

Richard W Peck1.   

Abstract

Understanding the basis of variability in the response of patients to the dose of a drug and a willingness to vary the dose regimen as well as the choice of drug should be one of the key pillars of precision medicine.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26669674     DOI： 10.1038/nrd.2015.22

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  5 in total

Review 1.  Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?

Authors:  A Grahnén; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  The combination of exposure-response and case-control analyses in regulatory decision making.

Authors:  Jun Yang; Hong Zhao; Christine Garnett; Atiqur Rahman; Jogarao V Gobburu; William Pierce; Genevieve Schechter; Jeffery Summers; Patricia Keegan; Brian Booth; Yaning Wang
Journal:  J Clin Pharmacol       Date:  2013-01-24       Impact factor: 3.126

3.  Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.

Authors:  J Wang; P Song; S Schrieber; Q Liu; Q Xu; G Blumenthal; L Amiri Kordestani; P Cortazar; A Ibrahim; R Justice; Y Wang; S Tang; B Booth; N Mehrotra; A Rahman
Journal:  Clin Pharmacol Ther       Date:  2014-01-31       Impact factor: 6.875

4.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Atsushi Ohtsu; Manish A Shah; Eric Van Cutsem; Sun Young Rha; Akira Sawaki; Sook Ryun Park; Ho Yeong Lim; Yasuhide Yamada; Jian Wu; Bernd Langer; Michal Starnawski; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

5.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  5 in total
  15 in total

1.  The pharmaceutical industry needs more clinical pharmacologists.

Authors:  Richard Peck
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

2.  CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Authors:  Jasmine A Luzum; Kevin M Sweet; Philip F Binkley; Tara J Schmidlen; Joseph P Jarvis; Michael F Christman; Wolfgang Sadee; Joseph P Kitzmiller
Journal:  Pharm Res       Date:  2017-02-08       Impact factor: 4.200

3.  A Dopamine D1 Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory.

Authors:  Yang Yang; Mechelle M Lewis; Lan Kong; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2022-06-05       Impact factor: 4.402

Review 4.  Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management.

Authors:  Zhining Wen; Yu Liang; Yingyi Hao; Brian Delavan; Ruili Huang; Mike Mikailov; Weida Tong; Menglong Li; Zhichao Liu
Journal:  Drug Discov Today       Date:  2018-06-11       Impact factor: 7.851

5.  Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Authors:  Thomas M Polasek; Geoffrey T Tucker; Michael J Sorich; Michael D Wiese; Titus Mohan; Amin Rostami-Hodjegan; Porntipa Korprasertthaworn; Vidya Perera; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-11       Impact factor: 4.335

Review 6.  Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.

Authors:  Ignacio Segarra; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño
Journal:  Front Pharmacol       Date:  2017-07-21       Impact factor: 5.810

7.  The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients.

Authors:  Wanghao Chen; Qiang Yu; Bo Chen; Xingyu Lu; Qiaoyu Li
Journal:  Oncotarget       Date:  2016-08-16

Review 8.  Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer.

Authors:  Matthew T McKenna; Jared A Weis; Amy Brock; Vito Quaranta; Thomas E Yankeelov
Journal:  Transl Oncol       Date:  2018-04-16       Impact factor: 4.243

Review 9.  Breast cancer: The translation of big genomic data to cancer precision medicine.

Authors:  Siew-Kee Low; Hitoshi Zembutsu; Yusuke Nakamura
Journal:  Cancer Sci       Date:  2017-12-30       Impact factor: 6.716

10.  Personalized Integrated Network Modeling of the Cancer Proteome Atlas.

Authors:  Min Jin Ha; Sayantan Banerjee; Rehan Akbani; Han Liang; Gordon B Mills; Kim-Anh Do; Veerabhadran Baladandayuthapani
Journal:  Sci Rep       Date:  2018-10-08       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.